ID: ALA2315103

Max Phase: Preclinical

Molecular Formula: C23H20F3N5O2

Molecular Weight: 455.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(Nc1ccccc1)c1ccc(N2CCN(C(=O)c3ccccc3C(F)(F)F)CC2)nn1

Standard InChI:  InChI=1S/C23H20F3N5O2/c24-23(25,26)18-9-5-4-8-17(18)22(33)31-14-12-30(13-15-31)20-11-10-19(28-29-20)21(32)27-16-6-2-1-3-7-16/h1-11H,12-15H2,(H,27,32)

Standard InChI Key:  XILJDMHVCGVOES-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 455.44

Molecular Weight (Monoisotopic): 455.1569

AlogP: 3.71

#Rotatable Bonds: 4

Polar Surface Area: 78.43

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.36

CX LogP: 3.76

CX LogD: 3.76

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.65

Np Likeness Score: -2.07

References

1. Zhang Z, Sun S, Kodumuru V, Hou D, Liu S, Chakka N, Sviridov S, Chowdhury S, McLaren DG, Ratkay LG, Khakh K, Cheng X, Gschwend HW, Kamboj R, Fu J, Winther MD..  (2013)  Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.,  56  (2): [PMID:23245208] [10.1021/jm301661h]

2. Llona-Minguez S, Höglund A, Ghassemian A, Desroses M, Calderón-Montaño JM, Burgos Morón E, Valerie NCK, Wiita E, Almlöf I, Koolmeister T, Mateus A, Cazares-Körner C, Sanjiv K, Homan E, Loseva O, Baranczewski P, Darabi M, Mehdizadeh A, Fayezi S, Jemth AS, Warpman Berglund U, Sigmundsson K, Lundbäck T, Jenmalm Jensen A, Artursson P, Scobie M, Helleday T..  (2017)  Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.,  60  (10): [PMID:28508636] [10.1021/acs.jmedchem.7b00182]

Source

Source(1):

• Scientific Literature